Skip to content

Observations for effects of supervised oral protein and low phosphorus supplementation during dialysis on nutritional status indicators

Observations for effects of supervised oral protein and low phosphorus supplementation during dialysis on nutritional status indicators

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023481
Enrollment
Unknown
Registered
2019-05-30
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uremia

Interventions

the ONS group:Those in the ONS group received a can of ONS during each hemodialysis session to ensure compliance
the CON group:Those in the control group increased their dietary intake without supplements

Sponsors

Zhejiang Provincial People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patients with maintenance hemodialysis, with stable condition and regular dialysis for more than 3 months, and the dialysis program remains unchanged before and after enrollment; 2. patients aged 18 to 80 years old with good compliance; 3. blood phosphorus level before dialysis >1.51mmol/L (normal range of blood phosphorus is 0.85-1.51mmol /L) 4. serum albumin level before dialysis =38g/L 5. voluntarily agree to participate in this study and maintain a stable diet during the experimental process.And sign the informed consent in accordance with regulations;

Exclusion criteria

Exclusion criteria: 1. patients with severe gastrointestinal motility diseases that affect calcium and phosphorus absorption; 2. patients with high blood glucose (including type 2 diabetes) and no blood glucose control therapy; 3. women who are pregnant or lactating or who are approaching menopause; 4. other systemic diseases affecting bone metabolism; 5. severe heart, lung, brain, psychosis and other severe primary diseases; 6. lactose intolerant.

Design outcomes

Primary

MeasureTime frame
height;grip strength;skinfold thickness;Body composition analysis;Upper arm muscle circumference;weight;

Countries

China

Contacts

Public ContactYiwen Li

Zhejiang Provincial People’s Hospital

yiwen1962@163.com+86 13456775925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026